구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Humira (adalimumab) | Enbrel (etanercept) |
Overview Company | AbbVie | Amgen / Pfizer |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | TNF (decoy receptor) |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | RA, PsA, AS, plaque psoriasis, JIA |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | novel object recognition test | novel ADAM17 inhibitor drugs to block soluble TNF-α production in inflammatory diseases |
Positioning Known limitation | Anti-drug antibodies, TNF-independent inflammation, and immunogenicity lowering trough levels. | Anti-drug antibodies (lower vs mAb TNF inhibitors), non-TNF pathways. |
MoA Mechanism | Adalimumab binds specifically to TNF-α and blocks its interaction with p55 and p75 cell-surface TNF receptors, neutralizing TNF-mediated inflammatory cascades (IL-6, adhesion molecules, acute-phase proteins). | Etanercept is a dimeric fusion protein of human p75 TNF receptor linked to IgG1 Fc; it binds TNF-α and lymphotoxin-α, preventing receptor activation and downstream NF-κB inflammatory signaling. |
MoA Biomarker | CRP, ESR, disease-specific scores (DAS28, PASI, Mayo for IBD). | DAS28, PASI, CRP. |
PK/PD Half-life | ~14–19 days (SC) | 30 h |
PK/PD Species | Rat, xenografts, which corroborat, CRP reduction, clinical remission scores | Rat, CRP, joint counts, skin scores |
PK/PD Animal (cat.) | Rat | Rat, In vitro |
PK/PD Experiment | pd | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Rat, xenografts, which corroborat | Rat |
Toxicology Animal (cat.) | NHP | — |
Toxicology Major finding | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. |
Toxicology CRS | N/A | N/A |
Clinical Safety signal | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. |
Clinical Selected reported efficacy | — | 73.4% |
Clinical PASI75 | — | PASI 75 response rate at Week 12. |
Clinical Result source | ClinicalTrials.gov NCT02405780 | ClinicalTrials.gov NCT01891864 |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02405780 | NCT01891864 |
Preclinical Animal (cat.) | — | Rat |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Humira (adalimumab) | Enbrel (etanercept) |
Overview Company | AbbVie | Amgen / Pfizer |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | TNF (decoy receptor) |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | RA, PsA, AS, plaque psoriasis, JIA |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | novel object recognition test | novel ADAM17 inhibitor drugs to block soluble TNF-α production in inflammatory diseases |
Positioning Known limitation | Anti-drug antibodies, TNF-independent inflammation, and immunogenicity lowering trough levels. | Anti-drug antibodies (lower vs mAb TNF inhibitors), non-TNF pathways. |
MoA Mechanism | Adalimumab binds specifically to TNF-α and blocks its interaction with p55 and p75 cell-surface TNF receptors, neutralizing TNF-mediated inflammatory cascades (IL-6, adhesion molecules, acute-phase proteins). | Etanercept is a dimeric fusion protein of human p75 TNF receptor linked to IgG1 Fc; it binds TNF-α and lymphotoxin-α, preventing receptor activation and downstream NF-κB inflammatory signaling. |
MoA Biomarker | CRP, ESR, disease-specific scores (DAS28, PASI, Mayo for IBD). | DAS28, PASI, CRP. |
PK/PD Half-life | ~14–19 days (SC) | 30 h |
PK/PD Species | Rat, xenografts, which corroborat, CRP reduction, clinical remission scores | Rat, CRP, joint counts, skin scores |
PK/PD Animal (cat.) | Rat | Rat, In vitro |
PK/PD Experiment | pd | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Rat, xenografts, which corroborat | Rat |
Toxicology Animal (cat.) | NHP | — |
Toxicology Major finding | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. |
Toxicology CRS | N/A | N/A |
Clinical Safety signal | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. |
Clinical Selected reported efficacy | — | 73.4% |
Clinical PASI75 | — | PASI 75 response rate at Week 12. |
Clinical Result source | ClinicalTrials.gov NCT02405780 | ClinicalTrials.gov NCT01891864 |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02405780 | NCT01891864 |
Preclinical Animal (cat.) | — | Rat |
추천 비교
추천 비교